CXI Healthcare Technology Group Limited (KOSDAQ:900120)
South Korea · Delayed Price · Currency is KRW 2,920.00
-15.00 (-0.51%)
At close: Nov 13, 2026
KOSDAQ:900120 Revenue
In the fiscal year ending June 30, 2026, CXI Healthcare Technology Group had annual revenue of 49.48B KRW, down -14.16%. CXI Healthcare Technology Group had revenue of 17.33B in the quarter ending June 30, 2026, a decrease of -10.21%. That makes CXI Healthcare Technology Group the 30,002nd largest company in the world by revenue and 1,873rd in South Korea.
Revenue
49.48B
Revenue Growth
-14.16%
P/S Ratio
0.20
Revenue / Employee
1.90B
Employees
26
Market Cap
9.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 49.48B | -8.16B | -14.16% |
| Jun 30, 2025 | 57.64B | -11.78B | -16.97% |
| Jun 30, 2024 | 69.42B | -2.20B | -3.07% |
| Jun 30, 2023 | 71.62B | -29.76B | -29.35% |
| Jun 30, 2022 | 101.38B | -3.22B | -3.08% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hurum | 94.89B |
| ChoA Pharmaceutical Co., LTD. | 61.16B |
| WooGene B&G | 56.49B |
| Seoul Pharma | 51.08B |
| Kwangdong Healthbio | 38.10B |
| Union Korea Pharm | 25.45B |
| Daesung Microbiological Labs. | 25.20B |
| BIFIDO | 14.63B |